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Summary
Propionyl-CoA carboxylase (PCC) is a mitochondrial
biotin-dependent enzyme composed of an equal number
of a and b subunits. Mutations in the PCCA (a subunit)
or PCCB (b subunit) gene can cause the inherited met-
abolic disease propionic acidemia (PA), which can be life
threatening in the neonatal period. Lack of data on the
genomic structure of PCCB has been a significant im-
pediment to full characterization of PCCB mutant chro-
mosomes. In this study, we describe the genomic organ-
ization of the coding sequence of the human PCCB gene
and the characterization of mutations causing PA in a
total of 29 unrelated patients—21 from Spain and 8
from Latin America. The implementation of long-dis-
tance PCR has allowed us to amplify the regions en-
compassing the exon/intron boundaries and all the ex-
ons. The gene consists of 15 exons of 57–183 bp in size.
All splice sites are consistent with the gt/ag rule. The
availability of the intron sequences flanking each exon
has provided the basis for implementation of screening
for mutations in the PCCB gene. A total of 56/58mutant
chromosomes studied have been defined, with a total of
16 different mutations detected. The mutation spectrum
includes one insertion/deletion, two insertions, 10 mis-
sense mutations, one nonsense mutation, and two splic-
ing defects. Thirteen of these mutations correspond to
those not described yet in other populations. The mu-
tation profile found in the chromosomes from the Latin
American patients basically resembles that of the Span-
ish patients.
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Introduction
Propionyl-CoA carboxylase (PCC; EC 6.4.1.3) is a mi-
tochondrial, biotin-dependent enzyme involved in the
degradation of several essential amino acids (threonine,
valine, isoleucine, and methionine), fatty acids of odd-
numbered chain lengths, and cholesterol (Fenton and
Rosenberg 1995). It catalyzes the enzymatic carboxyl-
ation of propionyl-CoA to D-methylmalonyl-CoA in an
ATP-dependent process. PCC is a heteropolymeric en-
zyme composed of two types of subunits, an a subunit
(74 kD), containing the covalently attached biotin moi-
ety, and a b subunit (55 kD). Genetic deficiency of PCC
causes an inborn error of metabolism, termed “pro-
pionic acidemia” (PA). Two distinct genotypic forms of
PA have been distinguished by somatic cell complemen-
tation: pccA (MIM 232000) and pccBC (MIM 232050),
resulting frommutations in the PCCA or the PCCB gene,
respectively. The disorder is clinically heterogeneous,
with a severe ketoacidotic form that can be lethal in the
neonatal period and a mild, late-onset form that includes
developmental retardation and that may be associated
with episodic ketoacidosis.
Human a-PCC (Lamhonwah et al. 1989; Stankovics
and Ledley 1993) and b-PCC cDNAs (Ohura et al.
1993b; Lamhonwah et al. 1994) previously have been
cloned and characterized. Recombinant a-PCC and b-
PCC subunits have been expressed in both eukaryotic
(Stankovics and Ledley 1993; Lamhonwah et al. 1994)
and prokaryotic (Leon-Del-Rio andGravel 1994; Kelson
et al. 1996) expression systems. The PCCB cDNA con-
tains an open reading frame of 1,617 nucleotides, en-
coding a 539–amino acid polypeptide. The PCCB gene
is located on the long arm of human chromosome 3
(Kraus et al. 1986; Lamhonwah et al. 1986).
So far, mutations in the PCCB gene have been de-
scribed only in a few patients, who, in most cases, carry
mutations affecting the coding sequences. Until now, 13
putative disease-causing mutations, including RNA-
splicing defects, have been reported, occurring in Cau-
casian and Japanese patients (Lamhonwah et al. 1990;
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Tahara et al. 1990, 1993; Ohura et al. 1993a, 1993b,
1995; Gravel et al. 1994; Hoenicka et al. 1998). Several
of these mutations lie in the same exon, which spans
nucleotides 1199–1299, suggesting that this exon may
be a hot spot for mutations (Tahara et al. 1990, 1993;
Ohura et al. 1993a). The most frequent mutation found
in Caucasian patients is an insertion/deletion (ins/del)
(1218del14ins12) (Tahara et al. 1990, 1993; Pe´rez-
Cerda´ et al. 1994). Recently, we reported that c1170insT
is a frequent mutation among Spanish patients (Hoen-
icka et al. 1998). In Japan, the single-base substitution
T428I appears to be the most common disease-causing
mutation (Ohura et al. 1993a), underscoring the possible
independent origin of the mutations.
The lack of data on the PCCB gene structure has been
a significant impediment to full characterization of the
PCCB mutant chromosomes. In this article, we describe
the genomic organization of the coding region of the
PCCB gene. Each exon-intron boundary has been de-
fined. The information on genomic structure has enabled
us to perform a complete mutation analysis, for a total
of 29 unrelated PA patients—21 from Spain and 8 from
Latin America. A total of 16 different mutations were
detected. Eleven of these are described for the first time.
The mutation spectrum found in the chromosomes from
Latin American patients resembles that of the Spanish
patients. We speculate that the mutations could have
originated in Europe and were carried to the NewWorld
by the founding families.
Subjects and Methods
Subjects
In this study we included 32 patients (including three
pairs of siblings) from 29 unrelated families with doc-
umented PA due to a deficiency in the PCCB gene.
Twenty-three patients from 21 unrelated families are
from different regions of Spain. The remaining patients
are from Latin American countries (7 from Chile, 1 from
Brazil, and 1 from Ecuador).
For all the patients, some of whom have been reported
elsewhere (Del Valle et al. 1982; Pe´rez-Cerda´ et al.
1998), diagnosis of PA was based on clinical symptoms
and biochemical analysis. The deficiency was confirmed
by assaying PCC carboxylase activity in lymphocytes
and/or skin fibroblasts, by use of the method described
by Suormala et al. (1985). The cell cultures were main-
tained in Minimum Essential Medium (MEM; GIBCO-
BRL) supplemented with 1% glutamine, 10% FCS, and
antibiotics.
Assignment of cell lines to the major complementation
groups was achieved by (1) estimation of PCC activity
and the ratio between PCC and b-methylcrotonyl-CoA
carboxylase activity in parents’ fibroblasts (Wolf andRo-
senberg 1978); (2) complementation studies that tested
fusion of the patients’ skin fibroblasts with representa-
tive cell lines from the major complementation groups,
pccA (line 117, kindly provided by R. A. Gravel, Mon-
treal) and pccBC (line GMO3590, from the National
Institute of General Medical Sciences Human Genetic
Mutant Cell Repository), by use of a solution of 50%
PEG 4000 in MEM, in accordance with the procedure
previously described by Gravel et al. (1994); and (3)
ascertainment of the presence of functional a subunit in
cultured fibroblasts labeled with 3H-biotin, in accor-
dance with the method of Lam Hon Wah et al. (1983).
Fibroblasts, lymphocytes, peripheral blood leukocytes,
and dried blood spots were also obtained from at least
20 unrelated controls and were used as RNA and/or
DNA sources.
Exon-Intron Boundaries
Genomic DNA, isolated in accordance with the
method described by Old (1986), was used as template
for the analysis of PCCB gene organization. The exon-
intron boundaries were defined by generation, by use of
long-distance PCR, of overlapping intron-containing ge-
nomic fragments encompassing the entire coding se-
quence of the PCCB gene. Amplification reactions were
performed by means of the XL PCR kit (Perkin Elmer),
in a final volume of 50 ml, by use of 300 ng genomic
DNA. The Mg(OAC)2 concentration (1.2–1.5 mM) and
annealing temperature (61C–66C) were optimized for
each primer set used. Thirty cycles of two-step PCR am-
plification were performed, each consisting of 20 s of
denaturation at 94C and 6–10 min at the annealing
temperature, with lengthening of the annealing step by
15-s increments for each of the last 15 cycles. After a
final 10-min extension at 72C, the reaction products
were electrophoresed on 0.8% agarose gels, purified by
Gene Clean, and direct sequenced with fluorescently la-
beled primers, by use of the fmol DNA sequencing kit
(Promega). Sequences were analyzed on an automated
DNA sequencer (ALF Express, Pharmacia). Primers de-
rived from the PCCB cDNA sequence (Ohura et al.
1993a; Gravel et al. 1994) were used for the initial se-
quencing. The resulting sequence was compared with the
cDNA sequence, to identify exon-intron boundaries.
New intronic primers then were designed to obtain the
remaining exon-intron junctions. Some of the sequences
used to design the intronic primers were kindly provided
by D. Leclerc and R. A. Gravel. The size of each PCR
product was determined on an 0.8% agarose gel, by use
of DNA Molecular Weight Marker II (Boehringer
Mannheim).
Table 1
PCCB Primers Used for Exon Amplification
Exon
5′-Intron Primer
(5′r3′)
Distance
from Exon
(bp)
3′-Intron Primer
(5′r3′)
Distance from
Exon
(bp)
Length of
PCR Product
(bp)
EMBL
Accession No.
1 cDNA1: GCTCTAGACGCGCCGGCACAGCAA ) AS1: ccgggcacgcagtgataggtc 65 272 AJ006487
2 S184: cttcaagccctcccatgaacagc 85 AS184: ggtaggccagctgagccacacct 56 261 AJ006488
3 S304: ggcatagtggccaaactcattag 71 AS304: agttttcattccccaagattggc 92 232 AJ006489
4 S373: cactgggttttcatctctagc 64 AS373: gtacctagctcagtgtcttgt 94 215 AJ006490
5 S430: ctgtggtattttgtgaatgtcg 74 AS430: gccaggccatggcttagagaa 65 253 AJ006491
6 S544: tatctttccacagataatgcctc 67 AS544: caacctagatctgggtcagga 91 269 AJ006492
7 S655: gaatcaactctaaggctgtgacc 70 AS655: aggctctttggcaatgccctct 65 249 AJ006493
8 S764: gaagcagcaactttgggctggc 63 AS764: cctgtcagggcagagaaaggcaa 67 251 AJ006494
9 S885: aagcccagcagggacagaactgg 128 AS885: caagtggtccagtgcttcctcac 92 302 AJ006495
10 S965: gaaatgtcattctgtagtgtcat 79 AS965: gacagaaaggataccatggacc 77 280 AJ006496
11 S1091: ggatggctgctgaggacaaa 85 AS1091: tgggaaaggcaactctcctagcc 44 237 AJ006497
12 S1120: CGTTTTGTCAGATTCTGTGATGC 317 AS1199: cactactgccttccagttccc 198 616 AJ006497
13 S1237: GCCAAGCTTCTCTACGCATTTG 442 AS1300: agctatgccttgagctctcgc 72 613 AJ006497
14 S1399: cagttcctccctctatgctatg 157 AS1399: cactagtcaacagattagactgc 119 376 AJ006498
15 S1499: ctaccatctctgtatcaggttg 134 cDNA2: GCTCTAGACTTGGTTTCTTTTCCTTTGATTT ) 289 AJ006499
NOTE.—cDNA1 and cDNA2 are exon-based primers that were designed, by Ohura et al. (1993a), to be complementary to the 5
′ and 3′ UTRs of the human PCCB gene. S1120 and S1237
are exonic primers that hybridize to the preceding exon.
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Table 2
Alignment of the Exon and Intron Boundaries
EXON
SIZE
(bp) INTRON EXON INTRON
SCORE
3′ Acceptor Site 5′ Donor Site
1 x183 ) ATG GCG AAG CGA gtgagtcctgaggggcctaa ) 76.5
Met Arg
1 61
2 120 tgatctttgttccattgtag GGA AAG AAT AAG gtatttgttcaaatggtggt 89.0 74.3
Gly Lys
62 101
3 69 tttttgcatttttctggtag TTT CCT AGT CAG gtatttcataactccaatag 81.9 74.3
Phe Gln
102 124
4 57 gatttgtattttctttttaga GAT TTT TGC AAA gtaagtgtttaatactcaaab 91.3 87.6
Asp Lys
125 143
5 114 agatttctctgctgtctcag ATC ATG TTT CTG gtgagaaacctgttaataga 88.2 83.2
Ile Leu
144 181
6 111 ttgcttttctgttttggcag AGG AAT GTA AAG gtaagaaagaagggcctgtt 95.2 94.3
Arg Lys
182 218
7 109 ctggaaatcttttatttcag GAC ACC TCA G gtgagaggccttgaagatga 96.4 91.0
Asp Gly
219 255
8 121 tatgctccctgttctcttag GT GTG CCC AG gtgggttgtaggccggtgca 84.3 86.0
Gly Ser
255 295
9 82 tgccttttttctgcctaaag T GAC CAC TCT gtaagtgccacatctgtttga 80.0 79.0
Ser Ser
295 322
10 124 aagtaaatttattcctgcag GTT GTT TCA G gtaggatggagctcttataa 97.2 83.6
Val Gly
323 364
11 108 gataatctctctctttctag GA TGC CCT G gtaagtttttgacagagtgg 88.0 92.1
Gly Gly
364 400
12 101 taactcttcctcatgtctagc GC ACA AGG AAG gtgaggacctcatgttggagc 83.7 92.1
Gly Lys
400 433
13 99 agcatttggatctgttttag GCC TAT GCA AAG gtgagggcctcttgcttttc 77.6 92.1
Ala Lys
434 466
14 100 atgaactcctctaatcacag GGC GCT CGA G gtaggggactgtggtgaaga 92.2 84.7
Gly Gly
467 500
15 x122 ccttttctgtgcttcaccag GG TTT TTG TAA ) 87.3 )
Gly Leu Stop
500 539
a Data from R. A. Gravel (personal communication).
b 5′ donor site reported by Ohura et al. (1995).
c 5′ donor site and 3′ acceptor site reported by Tahara et al. (1990).
PCR Amplification of Exons
cDNA1 and cDNA2 sequences correspond to primers
designed previously, by Ohura et al. (1993a), to be com-
plementary to the 5′ and 3′ UTRs, respectively, of the
PCCB gene. The other primers basically were designed
to amplify each PCCB exon and at least 40 bp of the
surrounding intron sequence (table 1). PCR was per-
formed in a final volume of 100 ml, by use of 0.5–1 mg
genomic DNA, 0.2 mM each primer, 0.25 mM each
dNTP, 1.5 mMMgCl2, 10% dimethyl sulfoxide, and 0.5
units AmpliTaq (Perkin-Elmer). A “hot” start was per-
formed, followed by 30 cycles of 1 min at 94C, 1 min
at 55C, and 1 min at 72C, by use of a Peltier Thermal
Cycler PTC-200. To amplify exon 1, the annealing tem-
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Table 3
Mutations Identified in the PCCB Gene
MUTATIONa NUCLEOTIDE CHANGE
EFFECT ON COD-
ING SEQUENCEb
RESTRICTION-
SITE CHANGEc
FREQUENCY (%) OF ALLELE
Spain Latin America
ins/del 1218del14ins12 fs and stop codon MspI 13/42 (31.0) 7/16 (43.7)
c1170insT ins of T at 1170–1174 fs and stop codon ) 7/42 (16.7) 1/16 (6.2)
E168K 502GrA Glu168Lys MboII (ACRS) 6/42 (14.3) 4/16 (25.0)
A497V 1490CrT Ala497Val BsoFI 4/42 (9.5) 0/16 (0)
G198D 593GrA Gly198Asp AvaII 2/42 (4.8) 0/16 (0)
R44P 131GrC Arg44Pro MspI 1/42 (2.4) 0/16 (0)
S106R 318CrA Ser106Arg BstUI (ACRS) 1/42 (2.4) 0/16 (0)
G131R 391GrC Gly131Arg MnlI 1/42 (2.4) 0/16 (0)
R165W 493CrT Arg165Trp NlaIII 0/42 (0) 1/16 (6.2)
R410W 1228CrT Arg410Trp MspI 1/42 (2.4) 1/16 (6.2)
1298-1299insA ins of A at 1297–1299 fs and stop codon ) 0/42 (0) 1/16 (6.2)
R512C 1534CrT Arg512Cys PmlI 1/42 (2.4) 0/16 (0)
L519P 1556TrC Leu519Pro MspI 1/42 (2.4) 0/16 (0)
W531X 1593GrA Trp531Stop StyI 1/42 (2.4) 0/16 (0)
IVS13GrC 1833GrC Splice mutation BsaI (ACRS) 1/42 (2.4) 0/16 (0)
IVS10-11del6 1091-11del6 Splice mutation ) 1/42 (2.4) 0/16 (0)
Total no. (%) identified ) ) ) 41/42 (97.6) 15/16 (93.7)
a Mutations that have not been described yet in other populations are underlined. Designations correspond to those described
by Antonarakis and the Nomenclature Working Group (1998), except for “ins/del” and “c1170insT,” which had been named
previously.
b fs  frameshift.
c ACRS  amplification created restriction site.
perature was 60C. In some cases, PCR amplifications
were performed directly by use of dried blood spots as
the source of DNA (Pe´rez et al. 1993).
Mutation Analysis
Reverse transcriptase PCR (RT-PCR)–based methods
were used initially, to identify mutations and to confirm
the predicted consequences of splice mutations. The total
fibroblast RNA (1 mg), isolated in accordance with the
method of Chomczynski and Sacchi (1987), was used
for first-strand cDNA synthesis. PCCB cDNA was am-
plified in five overlapping fragments of ∼400 bp in
length, by use of the primers and the amplification con-
ditions described elsewhere (Ohura et al. 1993a; Gravel
et al. 1994).
Mutations also were detected by amplification of
PCCB exons from genomic DNA of fibroblasts, followed
by direct cycle sequencing, with the fmol sequencing sys-
tem (Promega), of 100 ng of the PCR products, as de-
scribed above. Prior to sequencing, the PCR-amplified
fragments were purified by use of the Wizard PCR Preps
DNA purification system (Promega).
Detection of certain mutations, as well as analysis of
control chromosomes, was accomplished by restriction
digestion analysis of PCR products, either directly or
after creation of the restriction site during amplification.
Digestion conditions were in accordance with the man-
ufacturers’ protocols. After digestion, fragments were
electrophoresed on 4% Nusieve gels.
Western Blot Analysis
Western blot analysis was performed in accordance
with standard procedures. The primary antibody used
was affinity-purified anti–b-PCC produced in rabbit by
immunization with purified b-PCC expressed in Escher-
ichia coli as fusion protein maltose binding pro-
tein–PCCB, by use of the pMAL expression system, as
described by Richard et al. (1997).
Results
Exon-Intron Boundaries
To determine the structure of the coding sequence of
the PCCB gene, we performed long-distance PCR with
genomic DNA and primers hybridizing to PCCB cDNA
sequences. Following the initial reactions, new primers
were designed on the basis of our increasing knowledge
of the gene structure. Using this strategy, we successfully
amplified genomic DNA fragments, from 2 kb to ∼20
kb in size, that spanned the entire coding sequence.
Alignment of these genomic PCR products demonstrated
that the coding region of the PCCB gene consists of 15
exons of 57–183 bp in size. All exon-intron splice junc-
tions conformed to the eukaryotic 5′ donor–3′ acceptor
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Figure 1 Mutations in the human PCCB gene. The locations of
the PCCB mutations are shown in the schematic representation of the
exonic structure of the gene. Mutations that have not been described
yet in other populations are shown in boldface.
Figure 2 Western blot analysis of the b-PCC subunit from PA
patients. Cell extracts of confluent fibroblasts containing equal
amounts of total protein (120 mg) were immunoprecipitatedwith poly-
clonal anti–human b-PCC. Lane C, Control cell line. Lanes 1 and 3–5,
Extracts from PCCB-deficient patients (SSL, PRG, MRA, and JGG,
respectively). Lane 2, Extract from the PCCA-deficient patient, SAG
(Richard et al. 1997).
consensus splice junction gt/ag rule (Stephens and
Schneider 1992). Junctions at introns 1, 2, 3, 4, 5, 6, 9,
12, and 13 were type 0 (splicing occurring between co-
dons); junctions at introns 7, 10, 11, and 14 were type
1 (splicing occurring after the first base of the codon);
and the junction at intron 8 was type 2 (splicing occur-
ring after the second base of the codon). All exon-intron
boundaries are listed in table 2. The splice sites were
scored in accordance with the method described by Sha-
piro and Senepathy (1987): scores for donor sites varied
within the range 74.3–94.3. The acceptor sites scored
within the range 77.6–97.2.
To facilitate detection of mutations by restriction di-
gestion and/or direct sequence analysis of genomicDNA,
sets of intronic oligonucleotide primers were designed
and tested for their ability to amplify individual exons
and the immediately flanking intronic sequences (table
1). Amplification of exons 12 and 13 was performed
with sense exonic primers (in capital letters in table 1),
hybridized to the preceding exon and previously de-
signed for a different use. The exon sequences are iden-
tical to those of the corresponding region in the cDNA.
Mutation Spectrum
In this study, we included 29 unrelated PA pa-
tients—21 from Spain and 8 from Latin America (6 from
Chile, 1 from Brazil, and 1 from Ecuador). All of them
had been assigned to the major complementation group
pccBC and, therefore, were selected as having a PCCB
mutation, as described in Subjects and Methods.
All patients were screened for the most frequent mu-
tations found previously in chromosomes from Spanish
PA patients—namely, an ins/del (1218del14ins12) and
c1170insT (1173-1174insT) (Pe´rez-Cerda´ et al. 1994;
Hoenicka et al. 1998). The ins/del was found to be pres-
ent on 31% of the alleles from Spanish patients and 47%
of the alleles from Latin American patients. However,
the second most frequent mutation in Spain, c1170insT
(frequency 16.7%), was found in only one chromosome,
from a Chilean patient (frequency 6%) (table 3).
Mutation analysis of the remaining mutant chromo-
somes was performed by sequencing of the PCR prod-
ucts obtained, after amplification of the 15 PCCB exons,
from genomic DNA and from those fragments derived
from reverse-transcribed RNA (i.e., from RT-PCR).
Most of the mutations were confirmed further by re-
striction-enzyme digestion.
Using this approach, we characterized the two mutant
alleles in 27 patients, which account for 97.6% (41/42)
of the mutant alleles from Spanish patients and 93.7%
(15/16) of the mutant alleles from Latin American pa-
tients. Of these patients, ∼38% are homozygous for one
mutation, and close to 62% are compound heterozy-
gotes for two different mutations. The mutation spec-
trum includes one ins/del, two insertions, 10 missense
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Table 4
Genotypes and Western Blot Analysis of the PCCB-Deficient Patients
Patient(s) Mutationsa Western Blotb Origin (n)
ALT, CBV, MRA, LMC, DTV ins/del, ins/del  Spain (3), Chile (2)
SSL, APJ c1170insT, c1170insT  Spain (2)
PRG, NGA E168K, E168K c Spain (1), Chile (1)
SVL A497V, A497V c Spain (1)
CTGd G198D, G198D NS Spain (1)
LGA, JGG, FM ins/del, E168K c Spain (2), Chile (1)
VMP ins/del, A497V c Spain (1)
AJA ins/del, R44P c Spain (1)
AG ins/del, W531X c Spain (1)
EAC ins/del, R512C  Spain (1)
PPM ins/del, R165W c Ecuador (1)
PVD ins/del, G131R  Spain (1)
DMS, HMM c1170insT, E168K c Spain (1), Chile (1)
PHH c1170insT, L519P c Spain (1)
CJF A497V, S106R NS Spain (1)
MBG E168K, IVS13GrC c Spain (1)
OVEe R410W, IVS10-11del6 f Spain (1)
HM R410W, ND f Brazil (1)
LVA c1170insT, ND NS Spain (1)
MV ins/del, 1298-1299insA  Chile (1)
a ND  not detected.
b A plus sign () indicates the presence of the b subunit, and a minus sign () indicates the
absence of the b subunit. NS  not studied (fibroblasts not available).
c Two bands of b-PCC of normal and reduced size.
d Clinical report was published in the article by Del Valle et al. (1982).
e Clinical report was published in the article by Pe´rez-Cerda´ et al. (1998).
f b-PCC smaller than normal size.
mutations, one nonsense mutation, and two splice-site
alterations. The relative frequencies are shown in table
3. Mendelian inheritance of the mutations was con-
firmed by use of a restriction-digestion test, if available,
or by sequencing of DNA from family members.
Figure 1 shows the 16 PCCB mutations and their lo-
cations. Ten of the mutations found in the coding se-
quence were novel. One is an insertion, 1298-1299insA,
which inserts an extra A between positions 1297 and
1299 of exon 12, generating a frameshift and a stop
codon seven triplets downstream in the new frame. The
rest are missense and nonsense mutations (E168K,
A497V, R44P, G131R, G198D, R512C, L519P,W531X,
and G593A). To exclude the possibility of a polymor-
phism, each mutation also was analyzed in 40 normal
chromosomes, by restriction digestion of the respective
exons amplified by PCR. The R410W and R165W mu-
tations have been described elsewhere, in a study of Jap-
anese patients (Ohura et al. 1993a).
E168K is a 502GrA transition, located in exon 5,
that replaces the acidic polar glutamic residue with the
basic polar lysine residue. The allele frequency of this
mutation is 14.3% in Spain and 25% in Latin America.
This suggests that E168K may be a common mutation.
A497V is a 1490CrT transition that replaces the
small nonpolar alanine residue by the larger nonpolar
valine residue. This mutation has been detected in three
Spanish PA patients who are from the same small village
(Hoenicka et al. 1997). The resulting frequency of this
mutation is 9.5% in Spain.
Each of the remaining mutations was represented by
one or two alleles. The effect and nucleotide change of
each mutation are shown in table 3. R44P is a 131GrC
transversion occurring in exon 1, close to the putative
cleavage site of the leader peptide. R512C, L519P, and
W531X are clustered in exon 15 (fig. 1). W531X results
in a 1593GrA transition that changes a tryptophan to
a termination codon. Translation of this mutant mRNA
would result in a protein truncated by nine amino acid
residues in the C-terminal region.
Finally, as is shown in table 3 and figure 1, we also
found two splice-site mutations. IVS10-11del6 causes an
aberrant splicing of the PCCB mRNA, resulting in the
skipping of exon 11 (authors’ unpublished data), and
the novel IVS13GrC disrupts the 5′ donor site of in-
tron 1 and is predicted to affect the splicing efficiency
of exon 1, although this could not be demonstrated,
since the sense primer for RT-PCR hybridizes with this
region.
Western Blot Analysis
To study the possible effect of the mutations on the
size and/or quantity of the translated b-PCC, we per-
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formed western blot analysis of our PCCB mutant cell
lines (fig. 2 and table 4). The results indicated a total
absence of immunoreactive b-PCC in all patients who
were homozygous for the ins/del or c1170insT mutation
and in those patients who were compound heterozygotes
for the ins/del and 1298–1299insA, ins/del and R512C,
or ins/del and G131R mutations. Cell lines from patients
carrying the R410W mutation in combination with an-
other, different mutation showed a band smaller than
normal in size and quantity. For the remaining cell lines,
we observed a reproducible pattern of two different
bands, one apparently of normal size and the other
smaller than normal. For the control cell lines, a unique
band was obtained, and the PCCA mutant cell line that
was included as a negative control showed absence of
b-protein (fig. 2).
Discussion
The strategy of direct sequencing of long-distance
PCR products obtained from genomic DNA has resulted
in an effective method of determining the exon structure
of the PCCB gene. The gene consists of 15 exons. Se-
quences flanking splice junctions have been determined.
The 5′ donor and 3′ acceptor sites at the splice junctions
correlated well with published consensus sequences
(table 2).
The availability of gene sequence information pro-
vided the basis for implementation of a comprehensive
screening for genetic alterations, by use of genomic
DNA, in 29 unrelated PA patients—21 from Spain and
8 from Latin America. A total of 56/58 of the mutant
chromosomes has been defined, with 16 different mu-
tations detected. Thirteen of these mutations correspond
to those not described yet in other populations. The
population-frequency values for all these mutations con-
form to a spectrum of PCCB mutations consisting of
four prevalent mutations, accounting for close to 71%
of the total mutant alleles, and a high number of rarely
occurring mutations. It is interesting to note that six of
the single-base substitutions affect CpG sites, which sus-
tain a higher mutation rate (Cooper and Youssoufian
1988).
In two patients, one of the two mutant alleles could
not be characterized, suggesting that the mutations must
lie in the promoter region or elsewhere within the in-
tronic sequences. For the other patients, we can infer,
on the basis of different evidence, that the mutations
that were found are the likely cause of the deficiency.
These mutations are the only substitutions found in the
entire coding sequence and the exon-intron boundaries.
Several of them (A497V, E168K, the ins/del, and
c1170insT) appear to be common alleles. All mutations
are absent from normal chromosomes, and Mendelian
inheritance has been confirmed. Finally, to differentiate
between polymorphism and mutation, we also analyzed
the possible effect of the different changes on the stability
and/or function of the protein and the conservation of
the amino acid residue in b-PCC from different organ-
isms. The c1170insT, ins/del, and 1298-1299insA mu-
tations generate a frameshift with a considerable reduc-
tion of the protein sequence, resulting in the predicted
consequence of a truncated protein. Supporting this pre-
diction, western blotting of fibroblasts from patients
who are homozygous for both mutations or compound
heterozygotes for the ins/del and 1298-1299insA mu-
tations revealed a total absence of b-PCC. This effect
could be the result of a rapid posttranslational degra-
dation of the protein. The prediction of the effect of
missense mutations is more difficult. Point mutations,
such as R512C, R44P, and G131R, could induce a big
change in the direct environment of the mutated residue
and could dramatically influence protein stability or
function (Filippis et al. 1994). The total absence of im-
munoreactive protein, observed in the western blot of
patients who carry G131R or R512C in combination
with mutations producing undetectable levels of b-PCC,
such as the ins/del or c1170insT, support the hypothesis
that certain point mutations can be severe with regard
to protein stability.
On the other hand, mutations A497V, G131R, L519P,
R512C, G198D, and E168K are nonconservative
changes affecting amino acids that are highly conserved
in human (Swiss-Prot accession no. P05166; EMBL ac-
cession no. X73424), rat (Swiss-Prot P07633; EMBL
M14634), Bacillus subtilis (Swiss-Prot P54541; EMBL
D84432), Saccharomyces cerevisiae (Swiss-Prot P53003;
EMBL X92557), andMycobacterium leprae (Swiss-Prot
P53002; EMBL U00012). More controversial is the ef-
fect of the R44P mutation. Until now, the exact length
of the cleavable NH2-terminal leader peptide had not
been determined; however, a highly conserved amino
acid motif had been identified for the proteolitic cleavage
of several mitochondrial targeted proteins (Hendrick et
al. 1989). According to these published consensus se-
quences, R44P is a mutation affecting the mature pro-
tein, very close to the cleavage site.
With regard to the two mutations affecting splice sites,
we observed an aberrant splicing pattern for IVS10-
11del6, which might result in the loss of 36 amino acids
in b-PCC (authors’ unpublished data). The IVS13GrC
mutation is predicted to affect the splicing efficiency of
exon 1; however, the possible effect of this mutation, on
posttranslational mitochondrial transport and pro-
cessing of the protein, remains to be clarified.
Finally, the fact that three different muta-
tions—R512C, L519P, and W531X—are located in the
same exon suggests the presence of a hot spot for mu-
tations similar to that described elsewhere for exon 12
(Tahara et al. 1990, 1993; Ohura et al. 1993a). Ex-
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pression analysis of all these mutations will reveal their
functional consequences for the mutant protein and their
involvement in the disease phenotype.
The similarity of the mutation profile reported for the
chromosomes from both the Spanish and the Latin
American patients suggests that the PA mutations prob-
ably were introduced in the NewWorld after the historic
migration of southern European settlers, as has been
described for other genetic diseases, such as phenylke-
tonuria (Desviat et al. 1995). The presence of mutations
such as R410W and R165W in Japanese patients could
be explained by a recurrence mechanism (Pe´rez-Cerda´
et al. 1998), because both of these mutations affect a
CpG dinucleotide. The higher frequency of the ins/del
and E168K mutations in Latin America could be ex-
plained by a number of different factors, including ge-
netic drift, or could be due to the specific geographic
origin of the European ancestors of this group of pro-
bands. The elucidation of the mutation spectrum in dif-
ferent European populations will help to clarify this
point.
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